Strategies to Maximize AI-Driven New Drug Development Outcomes
The Korea Pharmaceutical and Bio-Pharma Manufacturers Association announced on the 4th that, in collaboration with the Ministry of Health and Welfare and the Korea Health Industry Development Institute, it will hold a Pharmaceutical and Bio Innovation Forum under the theme "AI-Driven New Drug Development, A New Era of Pharmaceutical and Bio Innovation" on the 19th at the Lotte Hotel in Sogong-dong, Seoul.
Exterior view of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association in Bangbae-dong, Seocho-gu, Seoul. [Photo by Korea Pharmaceutical and Bio-Pharma Manufacturers Association]
This forum, aimed at stakeholders in the AI and new drug development sectors closely related to the pharmaceutical and bio industries, will consist of keynote presentations by leading experts and a policy discussion session.
The presentation topics include ▲The Present and Future of AI-Driven New Drug Development (Professor Kim Sun, Seoul National University) ▲AI New Drug Development and Big Data Utilization Strategies (Professor Kim Sang-su, Soongsil University) ▲Strategies for Activating Data Sharing and Utilization of Federated Learning (FL) Technology (Professor Ye Jong-cheol, KAIST) ▲Global Trends in AI New Drug Development and Our Response (Kim Woo-yeon, Head of AI New Drug Development Support Center, Korea Pharmaceutical and Bio-Pharma Manufacturers Association) ▲AI-Driven New Drug Development, Innovation and Strategic Response of Pharmaceutical Companies (Han Tae-dong, Executive Director, Dong-A ST) ▲The Importance of Collaboration and Investment in AI New Drug Development (Kim Han-jo, Director, Standigm), among others.
Following the presentations, a policy discussion session titled "Maximizing AI New Drug Development Outcomes through Data Sharing and Collaboration" will be held. Attendees will include Shim Eun-hye, Director of Health and Medical Data Promotion Division at the Ministry of Health and Welfare; Ahn Young-jin, Director of Pharmaceutical Policy Division at the Ministry of Food and Drug Safety; Kim Yong-woo, Head of Pharmaceutical and Bio Industry Division at the Korea Health Industry Development Institute; as well as over 20 committee members from the AI New Drug Development Expert Committee and AI New Drug Development Council of the Pharmaceutical and Bio-Pharma Manufacturers Association.
This forum will highlight the importance of Federated Learning technology to activate AI new drug development. Federated Learning technology enables multiple pharmaceutical companies to train AI without aggregating their data in one place, allowing collaboration with competitors without disclosing proprietary data. Additionally, the forum will introduce the global status and competitiveness of AI new drug development and propose various measures to invigorate the AI new drug development ecosystem.
For more details, please refer to the official website of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association.
Pharmaceutical Bio Innovation Forum Poster. [Image provided by Korea Pharmaceutical and Bio-Pharma Manufacturers Association]
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
